Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 μg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma

Respiratory Medicine

Volumn 95, Issue 2, 2001, Pages 136-146

  Bateman, E D ^a   Silins, V ^b   Bogolubov, M ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Latvian Postgraduate and Continuing Medical Education Institute   (Latvia)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Diskus ; Equivalence; Fluticasone propionate; HFA 134a; Metered dose inhaler; Reversible obstructive airways disease; Salmeterol fluticasone propionate combination product

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; HYDROCORTISONE; PLACEBO; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPOTHESIS; INTERMETHOD COMPARISON; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; NIGHT; PARALLEL DESIGN; PATIENT CARE; PEAK EXPIRATORY FLOW; PHARYNGITIS; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; SYMPTOM; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

EID: 0034940142     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2000.1008     Document Type: Article

References (31)

1. The British guidelines on asthma management 1995 review and position statement
2. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
3. Comparison of addition of salmeterol to inhaled steroid with doubling of the dose of inhaled steroids
4. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma
5. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma
6. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases
7. Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 μg twice daily in treating moderate to severe asthma
8. Effect of inhaled formoterol and budesonide on exacerbations of asthma
9. A meta-analysis of increasing inhaled steroid or adding salmeterol in symptomatic asthma (MIASMA)
10. Salmeterol/fluticasone combination inhaler: A new, effective and well tolerated treatment for asthma
11. Salmeterol/fluticasone propionate (50/100 μg) in combination in a Diskus™ inhaler (Seretide) is effective and safe in children with asthma
12. Salmeterol and fluticasone propionate (50/250 μg) administered via combination Diskus inhaler: As effective as when given via separate Diskus inhalers
13. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma
14. Metered-dose inhalers and CFCs: What respiratory physicians need to know
15. Continuing patient care with metered-dose inhalers
16. CFCs and inhalers
17. Montreal protocol on substances that deplete the ozone layer
18. Comparison of Diskus inhaler, a new multidose powder inhaler with Diskhaler inhaler for the delivery of salmeterol to asthmatic patients
19. Comparative effectiveness of salmeterol/fluticasone propionate combination 50/500 BID delivered via metered dose inhaler or Diskus in patients with reversible airways obstruction
20. Assessing equivalence of inhaled drugs
21. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma
22. Regular inhaled beta-agonist treatment in bronchial asthma
23. Exacerbations of asthma: A descriptive study of 425 severe exacerbations
24. Effects of salmeterol on PEFR and symptom assessment immediately prior to and following an asthma exacerbation
25. A comparison of in-vitro drug delivery from two multi-dose powder inhalation devices
26. A comparison of in-vitro drug delivery from salbutamol Diskus and terbutaline Turbuhaler inhalers
27. Use of inhalation profiles from patients with severe obstructive lung disease using the Diskus inhaler and Turbuhaler inhaler to evaluate device performance ex vivo
28. Comparison of peak pressure drops through powder inhalers drug inspiration at maximum flow rate
29. A comparison of the ease of handling of the Diskus/Accuhaler inhaler and the Turbuhaler inhaler in children aged 6-12 years with asthma
30. Patient perception of the Diskus inhaler: A comparison with the Turbuhaler inhaler